By selectively targeting specific steps of the immune inflammation cascade, biologic drugs for severe asthma have substantially contributed to increase the standard of care, to reduce drug-related morbidity. and most importantly to ameliorate patients' quality of life. Upcoming molecules are going to provide a chance for severe phenotypes besides Th2 high through the interaction with epithelial and innate immunity. Some practical aspects including optimal treatment duration, the possibility of a dose treatment modulation, the place and relevance of ICS in best responders are still under debate. Long-term safety, especially when interacting with innate immunity needs to be further investigated.
Keywords: Anti IL-33; Benralizumab; Dupilumab; Mepolizumab; Omalizumab; Reslizumab; Severe asthma; Tezepelumab.
Copyright © 2020 Elsevier Inc. All rights reserved.